Influence of the Human Gut Microbiome on Xenobiotic Metabolism and Pharmacokinetic Outcomes: From Bench to Bedside.

INTRODUCTION: Pharmacomicrobiomics is the interdisciplinary area of research arising from studies demonstrating that the microbiota in the human colon dynamically regulates the metabolism of many medications. This review paper discusses how this microbiota may explain some of the variability observed in patient responses to medication, and describes the role of gut-associated microbial communities in the metabolism, effectiveness, and safety of drugs. METHODS: Using important scientific databases, a thorough and methodical review of the literature was carried out with an emphasis on preclinical and clinical research examining microbiota-drug interactions. Microbial biotransformation pathways, enzyme-mediated metabolism (such as β- glucuronidases, azoreductases, and reductases), and the impact of dysbiosis, probiotics, and antibiotics on drug pharmacokinetics were important topics. New computational and microbiome-based prediction methods were also assessed. RESULTS: The gut microbiota has a substantial impact on drug bioavailability, metabolism, enterohepatic recirculation, and toxicity, according to mounting data. Anticancer, cardiovascular, and antidiabetic medications are among the many therapeutic classes whose pharmacokinetics are changed by microbial enzymatic activity. Clinically significant variability in drug response is caused by microbiome disruptions, such as dysbiosis brought on by antibiotics. Promising methods for forecasting microbiota-driven pharmacokinetic variations are provided by recent developments in pharmacomicrobiomic profiling and in silico modelling. DISCUSSION: These results highlight the gut microbiota as an important but little-known factor influencing pharmacokinetic behaviour and treatment effectiveness. Combining pharmacogenomic frameworks with microbiome data could improve tailored medication treatment. However, issues like interindividual microbial diversity, a lack of analytical method standardisation, and a lack of adequate translational models continue to be major obstacles. CONCLUSION: Drug metabolism and pharmacokinetic variability are significantly influenced by the gut microbiota-drug axis. Optimising therapeutic outcomes, reducing side effects, and advancing precision pharmacotherapy are all possible with the integration of microbiome-based insights into clinical decision-making and drug development.